Event: ACTRIMS 2023

0:01:57

ACTRIMS Forum 2023 | Event Highlight

1:16:44

ECTRIMS / ACTRIMS 2023 - Insight into the latest MS research

0:02:35

ACTRIMS highlights: viral infections and MS

0:01:14

EBV & MS risk at ACTRIMS

0:01:35

ACTRIMS research priorities

0:02:56

Balancing Efficacy and Safety With MS Disease Modifying Therapies

0:19:14

MS Milan 2023: Research Insights from Day One

0:03:33

Impact of natalizumab on chronic active MS lesions

0:03:08

Switching from S1Ps or HETs to DRF: results from the EVOLVE-MS-1 study

0:03:17

The Importance of the ACTRIMS as a Stand Alone Meeting

0:02:34

Improving comprehensive MS care through innovative and specialized approaches

0:03:33

Remyelinating treatments under investigation in MS

0:03:09

CSF biomarker-based models to predict MS outcomes

0:06:01

Infectious mimickers of MS

0:02:59

The development of clinically useful biomarkers in MS

0:03:54

Real-world use of the MSDA test: a case series

0:03:21

Self-reported adherence and safety from the MASTER-2 & CLICK-MS studies of cladribine in MS patients

0:02:30

Four-year efficacy and safety of evobrutinib for relapsing MS

0:01:06

Advancements in MS imaging techniques: spinal cord imaging

0:07:58

Molecular mechanisms associated with MS progression, severity and phenotype

0:04:02

The effects of myelin loss and remyelination on visual cortical function

0:01:38

Changing approaches to cognitive assessment in MS

0:02:42

Cladribine treatment patterns in MS patients: a cross-sectional survey

0:03:27

Research on the visual system and MS